PMID- 34319626
OWN - NLM
STAT- MEDLINE
DCOM- 20220304
LR  - 20220304
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 47
IP  - 2
DP  - 2022 Feb
TI  - Comparative assessment of efficacy and safety of ambrisentan and bosentan in 
      patients with pulmonary arterial hypertension: A meta-analysis.
PG  - 146-156
LID - 10.1111/jcpt.13481 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: Two endothelin receptor antagonists, ambrisentan and 
      bosentan, have been demonstrated to be effective individually compared with 
      placebo in the treatment of patients with pulmonary arterial hypertension (PAH). 
      This network meta-analysis compared the efficacy and safety of ambrisentan and 
      bosentan in patients with PAH. METHODS: Clinical trials were identified from the 
      Cochrane Central Register of Controlled Trials (CENTRAL/CCTR), EMBASE and PubMed 
      databases. Weighted mean differences (MD) with 95% confidence intervals (CI) were 
      calculated for continuous outcomes (6-min walk distance [6MWD] and Borg dyspnoea 
      index [BDI]). Hazard ratio (HR) was calculated for binary outcomes, including 
      clinical worsening, discontinuation due to adverse events (AEs) and liver 
      dysfunction. Surface under cumulative ranking curve (SUCRA) was used to rank the 
      treatments in each index. RESULTS: Five clinical trials from four published 
      studies (total patients: n = 920) were included. Ambrisentan and bosentan showed 
      no significant difference in 6MWD (MD: -1.32; 95% CI: -27.87, 25.31, SUCRA score: 
      ambrisentan 0.73, bosentan 0.77), BDI (MD: -0.16; 95% CI: -0.98, 0.65, SUCRA 
      score: ambrisentan 0.83, bosentan 0.66), clinical worsening (HR: 0.99; 95% CI: 
      0.33, 2.94, SUCRA score: ambrisentan 0.75, bosentan 0.74) and discontinuation due 
      to AEs (HR: 0.84; 95% CI: 0.11, 5.86, SUCRA score: ambrisentan 0.47, bosentan 
      0.57). However, ambrisentan was significantly better than bosentan with respect 
      to abnormal liver function (HR: 23.18; 95% CI: 2.24, 377.20, SUCRA score: 
      ambrisentan 0.99, bosentan 0.02). WHAT IS NEW AND CONCLUSION: The results of this 
      network meta-analysis suggest that ambrisentan was similar to bosentan in 
      efficacy, while it exhibited better tolerability with respect to abnormal liver 
      function in comparison with bosentan, in patients with PAH.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Zhao, Qinhua
AU  - Zhao Q
AD  - Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji 
      University School of Medicine, Shanghai, China.
FAU - Guo, Na
AU  - Guo N
AD  - GlaxoSmithKline, Beijing, China.
FAU - Chen, Jun
AU  - Chen J
AD  - GlaxoSmithKline, Beijing, China.
FAU - Parks, Daniel
AU  - Parks D
AD  - GlaxoSmithKline, Collegeville, PA, USA.
FAU - Tian, Zhuang
AU  - Tian Z
AUID- ORCID: 0000-0003-1140-4062
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
LA  - eng
GR  - GlaxoSmithKline (China) R&D Company Limited/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20210728
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyridazines)
RN  - HW6NV07QEC (ambrisentan)
RN  - Q326023R30 (Bosentan)
SB  - IM
MH  - Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Bosentan/administration & dosage/adverse effects/*therapeutic use
MH  - Endothelin Receptor Antagonists/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Humans
MH  - Liver Function Tests
MH  - Network Meta-Analysis
MH  - Phenylpropionates/administration & dosage/adverse effects/*therapeutic use
MH  - Pulmonary Arterial Hypertension/*drug therapy
MH  - Pyridazines/administration & dosage/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Walk Test
OTO - NOTNLM
OT  - 6-min walk distance
OT  - Borg dyspnoea index
OT  - liver dysfunction
OT  - network meta-analysis
OT  - randomized controlled trials
EDAT- 2021/07/29 06:00
MHDA- 2022/03/05 06:00
CRDT- 2021/07/28 12:59
PHST- 2021/06/17 00:00 [revised]
PHST- 2021/05/07 00:00 [received]
PHST- 2021/06/29 00:00 [accepted]
PHST- 2021/07/29 06:00 [pubmed]
PHST- 2022/03/05 06:00 [medline]
PHST- 2021/07/28 12:59 [entrez]
AID - 10.1111/jcpt.13481 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2022 Feb;47(2):146-156. doi: 10.1111/jcpt.13481. Epub 2021 Jul 
      28.